< img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=4285980&fmt=gif" />
en
Search
Home
Customer Testimonials
Small Molecule
Mol2Med™ Integrated Services
Developability Assessment
API Form and Solid-State Research
Crystallization Development Services
Pre-formulation Studies
Formulation and Analytical Development
GMP Manufacturing
Clinical Supply
Crystal Bio Solutions
Biologics CMC Analytical Services
Bioanalytical and Biomarker Services
Technology
Solid Form Screening
Solid Form Developability Evaluation
Absolute Structure Determination
Crystallization Process Development
Conventional Oral Solid Dosage Forms
Bioavailability Enhancement for Insoluble Compounds & PROTAC & Oral Peptides
Mini-tablet
About Us
Our Company
Our History
Our People
Our Partner
Resources
News & Events
Knowledge Hub
Webinar Series
Careers
Talent Recruitment
Contact Us
Home
Customer Testimonials
Small Molecule
Mol2Med™ Integrated Services
Developability Assessment
Solid-State Characterization/FAST
pKa/LogP/LogD Measurements
Stability and Solubility Studies
In-Silico PBPK Modeling and Simulation
API Form and Solid-State Research
Solid Form Screening and Selection
Single Crystal Growth & Structure Determination
Solid-State NMR Analysis
Crystallization Development Services
Crystallization Development
Chiral Separation
Pre-formulation Studies
Comprehensive Physicochemical Property Evaluation
Excipient Selection and Compatibility Studies
Formulations for PK/Efficacy/Tox Studies
Animal Dosing Vehicle Selection
Amorphous Solid Dispersions
Formulation and Analytical Development
Formulation Development
Oral Solid Dosage Forms
Amorphous Solid Dispersion (Spray Drying & Hot-melt Extrusion)
Pediatric Formulation (Mini-tablet)
Analytical Chemistry
GMP Manufacturing
Clinical and Commercial Manufacturing
FIH-PMF-FMF Manufacturing
Clinical Supply
Crystal Bio Solutions
Biologics CMC Analytical Services
Bioanalytical and Biomarker Services
Technology
Solid Form Screening
Solid Form Developability Evaluation
Absolute Structure Determination
Crystallization Process Development
Conventional Oral Solid Dosage Forms
Bioavailability Enhancement for Insoluble Compounds & PROTAC & Oral Peptides
Mini-tablet
About Us
Our Company
Our History
Our People
Our Partner
Resources
News & Events
News
Events
Knowledge Hub
Technical Articles
Presentations
Case Studies
Whitepaper
ASD Series
Biologics
Webinar Series
Crystal Pharmatech Formulation Forum
2023-Mol2Med™ First-Time-Right Approach Webinar Series
Selecting the Right API Form and Formulation
Molecules-to-Medicine: Accelerating Drug Development through Collaboration
Advanced Characterization: Tools for Accelerating Molecules to Medicine
Crystal Bio Webinar
Careers
Talent Recruitment
Contact Us
E-mail us
+1-609-604-8303
bd_global@crystalpharmatech.com
cn
Small Molecule
Mol2Med™ Integrated Services
Developability Assessment
API Form and Solid-State Research
Crystallization Development Services
Pre-formulation Studies
Formulation and Analytical Development
GMP Manufacturing
Clinical Supply
Solid-State Characterization/FAST
pKa/LogP/LogD Measurements
Stability and Solubility Studies
In-Silico PBPK Modeling and Simulation
Solid Form Screening and Selection
Single Crystal Growth & Structure Determination
Solid-State NMR Analysis
Crystallization Development
Chiral Separation
Comprehensive Physicochemical Property Evaluation
Excipient Selection and Compatibility Studies
Formulations for PK/Efficacy/Tox Studies
Animal Dosing Vehicle Selection
Amorphous Solid Dispersions
Formulation Development
Oral Solid Dosage Forms
Amorphous Solid Dispersion (Spray Drying & Hot-melt Extrusion)
Pediatric Formulation (Mini-tablet)
Analytical Chemistry
Clinical and Commercial Manufacturing
FIH-PMF-FMF Manufacturing
Crystal Bio Solutions
Biologics CMC Analytical Services
Bioanalytical and Biomarker Services
High-Resolution Mass Spectrometry
Bioanalysis and Biomarker Services
Bio Analytics
Developability Assessment, Pre-formulation Study for IND Enabling
Product Quality Analysis
Additional Capabilities
Technology
Solid Form Screening
Solid Form Developability Evaluation
Absolute Structure Determination
Crystallization Process Development
Conventional Oral Solid Dosage Forms
Bioavailability Enhancement for Insoluble Compounds & PROTAC & Oral Peptides
Mini-tablet
About Us
Our Company
Our History
Our People
Our Partner
Resources
News & Events
Knowledge Hub
Webinar Series
News
Events
Technical Articles
Presentations
Case Studies
Whitepaper
ASD Series
Biologics
Crystal Pharmatech Formulation Forum
2023-Mol2Med™ First-Time-Right Approach Webinar Series
Selecting the Right API Form and Formulation
Molecules-to-Medicine: Accelerating Drug Development through Collaboration
Advanced Characterization: Tools for Accelerating Molecules to Medicine
Crystal Bio Webinar
Careers
Contact Us
Crystal Bio Webinar
Home
Resources
Webinar Series
Crystal Bio Webinar
Crystal Bio Webinar
Analytical Techniques to Assess the mRNA 5' Cap
Small Molecule
Mol2Med™ Integrated Services
Developability Assessment
API Form and Solid-State Research
Crystallization Development Services
Pre-formulation Studies
Formulation and Analytical Development
GMP Manufacturing
Clinical Supply
Quick Links
About Us
Events
Contact Us
bd_global@crystalpharmatech.com
+1-609-604-8303
U.S
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
Canada
6800 Kitimat Rd, Unit 1, Mississauga, Ontario, Canada L5N 5M1
China
No. 288, Jiangyun Road, Suzhou Industrial Park, Suzhou, China, 215123
Sitemap
Privacy Policy
Solid Form Screening
Solid Form Developability Evaluation
Absolute Structure Determination
Crystallization Process Development
The Purpose Behind Molecules to Medicine
Repurposing Dexmedetomidine into an Oral Sleep-Enhancing Medication
The Role of Collaboration in Optimizing the Development of HIF Inhibitors for the Treatment of Advan
Mol2Med™ Integrated Services
AAPS 2024 PHarmSCi 360
Concerned about mRNA -LNP Integrity during International Shipping?
Improving the Manufacture of mRNA Biologics
Home
Formulation Development
Solid Form Screening and Selection
Our Company
Talent Recruitment
Case Study 1: Indinavir - Early Salt Form Change
The Tiny-TIM System
Technical Articles
Solid Form Research
Engineering Cocrystal Solubility and Streamlining Cocrystal Early Development
The Use of Amorphous Solid Dispersions to Enhance Dissolution, and Oral Bioavailability of Poorly Water-Soluble Pharmaceutical C
Biologics CMC Analytical Services
High-Resolution Mass Spectrometry
Crystal Pharmatech Formulation Forum
News & Events
Optimizing Polymer Selection for Amorphous Solid Dispersion in Hot Melt Extrusion Processes
Unlocking the Power of AI in Pharmaceutical Development
Formulation & Delivery US 2024
Concerned about mRNA -LNP Integrity during International Shipping?
Analytical Techniques to Assess the mRNA 5' Cap
Small Molecule
Solid-State Characterization/FAST
Conventional Oral Solid Dosage Forms
Our History
News
Our Business
Case Study 2: DPC 961 – Form Change On A Fast Track Compound
Detecting and Avoiding Disappearing Polymorph Cases by Crystal Structure Prediction
Presentations
Preclinical and Tox Formulation Development
Synthonic Engineering: Tools for the Rational Design of High Quality Pharmaceuticals
Polymorphism of Drugs - Can We Exploit Physical Form in the Development of Low Solubility Molecules?
Bioanalysis and Biomarker Services
2023-Mol2Med™ First-Time-Right Approach Webinar Series
Date:
2:00-3:00 pm EDT, Wednesday,
Watch on-demand
Developability Assessment
Oral Solid Dosage Forms
Development and Production Application Cases of Amorphous Solid Dispersion Formulations (II) - Spray Drying
CATUG and Crystal Bio Establish Strategic Partnership, Launching “CATUG-Crystal” Joint Lab Dedicated to Advanced Nucleic Acid Analytical Services
Characterization and Evaluation of Amorphous Solid Dispersion - Part 2
ADME Simulations: Insights into Bioavailability and Pharmacokinetics
Utilizing Compaction Simulation for Advancing Oral Dosage Formulation Design
Critical Quality Attribute (CQA) in Antibody Drug Conjugate (ADC) Modality
The 16th Drug Discovery Strategic Summit (DDSS) - San Francisco
Bioanalytical and Biomarker Services
Single Crystal Growth & Structure Determination
Bioavailability Enhancement for Insoluble Compounds & PROTAC & Oral Peptides
Our People
Events
Case Study 3: Atorvastatin - Crystalline Form Change In Late Development
Selecting the Right API Form and Formulation
Instrumentation for Electron Diffraction, Applications, and Case Studies
Case Studies
Effective Development of API Crystallization Processes During Drug Development
Efficient Preclinical Formulation Development for Poorly Soluble Compounds
pKa/LogP/LogD Measurements
Date:
2:00-3:00 pm EDT, Wednesday,
Watch on-demand
Amorphous Solid Dispersion (Spray Drying & Hot-melt Extrusion)
Dr. LianFeng Huang Joins Crystal Pharmatech as Chief Scientist
Characterization and Evaluation of Amorphous Solid Dispersion (ASD) - Part 1
Characterization and Evaluation of Amorphous Solid Dispersion-Part 2
Parameter Sensitivity with GastroPlus
Critical Quality Attribute D0 Impact in ADC Modality
SAPA Annual Conference (Gold Corporate Sponsorship)
Crystal Bio Solutions
Bio Analytics
API Form and Solid-State Research
Crystallization Development
Mini-tablet
Knowledge Hub
Molecules-to-Medicine: Accelerating Drug Development through Collaboration
PBPK in Preclinical/FIH Scenarios
Whitepaper
Case Study 4: Gatifloxacin - Crystalline Form Changes With A Licensed Compound
Amorphous Solid Dispersions
Using Thermodynamic Phase Maps in API Crystallization Process Design
Pre-clinical Formulation Strategies Sponsored by Crystal Pharmatech
Date:
2:00-3:00 pm EDT, Wednesday,
Whatch on-demand
Stability and Solubility Studies
Comprehensive Physicochemical Property Evaluation
Pediatric Formulation (Mini-tablet)
Crystal Formulation Services successfully passed the dual certification of GMP and GDP conducted by SGS
Development and Production Application Cases of Amorphous Solid Dispersion Formulations (I) - Hot Melt Extrusion
Unveil Key Factors Influencing the Physical Stability of Amorphous Solid Dispersions
Assessment of CQA in mRNA-LNP Modality
Overcoming Bioavailability Barrier to Deliver Protein Degraders
14th American Drug Delivery and Formulation Summit (Exhibit)
Developability Assessment, Pre-formulation Study for IND Enabling
Product Quality Analysis
Additional Capabilities
Chiral Separation
Technology
Our Partner
Advanced Characterization: Tools for Accelerating Molecules to Medicine
Tools for Accessing New Solid Forms
Case Study 5: Lifecycle Management - Olanzapine - Crystalline Change From Free Acid to Salt
Enabling Poorly Soluble Weak Bases for Improved Bioavailability: Why a Salt May Not be the Best Choice
Integrated Phase and Formulation Selection to Support GLP Toxicology and First in Human Studies Sponsored by Crystal Pharmatech
In-Silico PBPK Modeling and Simulation
Industry Shift: FDA Goes Vegan?
Date:
2:00-3:00 pm EDT, Wednesday,
Watch on-demand
Crystallization Development Services
Excipient Selection and Compatibility Studies
Analytical Chemistry
ASD Series
Unlock Solubility Enhancement Methods for Poorly Soluble Oral Drugs
Development and Production Application Cases of Amorphous Solid Dispersion Formulations (II) - Spray Drying
Overcoming Poor Solubility and Dissolution of Insoluble Molecules
Patent Analysis of Resmetirom
Sterility Assays in Drug/Device Manufacturing
2024 CASSS - Mass Spec Symposium
Flow Cytometry
About Us
Pre-formulation Studies
Formulations for PK/Efficacy/Tox Studies
Crystallization and Spray Drying Process Development, Scale-Up, and Technology Transfer
Case Study 6: Oxybutynin- Crystalline Change From Salt to Free Base
Learn about Drug Eutectic Screening
Crystal Pharmatech's CDMO Business Unit - Crystal Formulation Services Received China Drug Product Manufacturing License, Achieving the Important Milestone in Formulation Capability
Development and Production Application Cases of Amorphous Solid Dispersion Formulations (I) - Hot Melt Extrusion
Review of Polymorph Patent Application of 30 Small Molecule New Drugs Approved by the FDA in 2023
Biologics
ChemOutsourcing 2024
Crystal Bio Webinar
ELISpot Assays
Solid-State NMR Analysis
Resources
Avoiding Drug Failures: Right First Time; Fast First Time
Exploring the Pharmaceutical Solid State by Molecular Simulation
Crystallization Process Method
SMART Development of Pre-clinical Candidates
Crystal Pharmatech Recognized as "Best Partner" by Allorion Therapeutics for Excellent Services
Formulation and Analytical Development
Animal Dosing Vehicle Selection
Detecting Low-Level Crystallinity in ASD-like Samples Using ssNMR Techniques
Understand ASD Manufacturing Strategies, Choose the Optimal One
Immuno-Oncology Summit 2024 - Meet Crystal Bio at Booth 15
Molecular Biology
Clinical and Commercial Manufacturing
Amorphous Solid Dispersions
Careers
Tools and Strategies for De-risking Rapid Drug Substance and Drug Product Development
API Crystallization
Crystal Pharmatech Returned to AAPS 2022 PharmSci 360
Fun Sharing: The Secret Behind the Silky Smoothness of Chocolate (Part 2)
GMP Manufacturing
A Brief Introdction to Amorphous Solid Dispersion Technology
Amorphous Solid Dispersions: Two Heads Are Better Than One
FIH-PMF-FMF Manufacturing
The Bioprocessing Summit 2024 - Meet Crystal Bio at Booth T13
Contact Us
Crystal Pharmatech and Particle Sciences Form a US-China Pharmaceutical CRO Partnership
Advancements in Analytical Tools for API and DP Characterization
Co-crystals
Fun Sharing: The Secret behind the Silky Smooth Enjoyment of Chocolate (Part 3)
Unlock Solubility Enhancement Methods for Poorly Soluble Oral Drugs
Meet Crystal Pharmatech at 2024 Controlled & Modified Drug Release Summit
Assessment of Powder Segregation in Direct Compression (DC) Blends: Developing Predictive and PAT Tools
Search Result
Webinar Series
Crystal Pharmatech Raises $10 Million to Accelerate Growth
Solid Forms: The Good; The Bad; The Ugly
Impact of Solid-state in Early Development
Fun Sharing: The Secret Behind the Silkiness of Chocolate (Part 1)
Join Crystal Pharmatech for the Sino-American Pharmaceutical Professionals Association (SAPA) NE 26th Annual Conference
Formulation Design and Development of Fixed Dose Combination Solid Oral Dosage Forms
Sitemap
Crystal Formulation Services, Formulation Tailor-made for Your Molecules
Utility of Single Crystal in Form and Formulation Selection
Optimal Preclinical Formulation Development
Crystal Pharmatech will be in San Diego from June 3-6 at BIO International Convention
Drug Delivery and Patient Centric Approaches to Drug Development
404
Candoo Enables the Successful Development of a BCS 4 Combo Drug Product
Introduction to MicroED Technology and Solutions
Salts
Fun Sharing:The Story Between Ice Crystals and Frozen Foods (Part 3)
Meet Crystal Pharmatech at Chinese Antibody Society 2024 Annual Conference
Privacy Policy
International Company Crystal Pharmatech Finds CCIT An Optimal Spot for First US Location
Formulation Implications
Pharmaceutical Solid-state Forms
Meet Crystal Pharmatech at 15th Drug Discovery Strategic Summit (DDSS)
Submission Successful!
Crystal Pharmatech Triples Headquarters in Biobay, China, with More Floors and Labs
Fun Sharing: The Relationship Between Ice Crystals and Frozen Foods (Part 1)
Clinical Supply
Meet Crystal Pharmatech at Sorption Symposium North America 2024
Taggg
Xceleron and Crystal Pharmatech Announce Partnership to Improve Early Clinical Development Utilizing Absolute Bioavailability Trials and Solid-State Solutions
CPHI North America - Meet Crystal Pharmatech at Booth 1441
Search Result Service
Crystal Pharmatech Introduces Customized Service Packages for Customers Seeking Materials Science Approaches in Drug Discovery and Development
Fun Sharing: The Story of Ice Crystals and Frozen Foods (Part 2)
Meet Crystal Pharmatech at MIDD+ Boston 2024
Search Result Others
Crystal Pharmatech Expands Leadership Team
Case Study on Development and Production Applications of Amorphous Solid Dispersions - Hot Melt Extrusion
Formulation Development: Fastest-to-FIH Without Sacrificing Quality
Crystal Formulation Services(CFS)Opens New Formulation Development Center and Analytical R&D Lab in Suzhou, China
event page
Development and Production Application Case Study of Amorphous Solid Dispersions: Spray Drying
DCAT WEEK: CMC Discussions
Amorphous Solid Dispersion Technology and the Service Advantages of Crystal Pharmaceutical
AAPS PharmSci360 - Meet Us at Booth # 2106
Candoo's Formulation Technology Platform Featured in the Drug Development & Delivery Journal
ASD Column | Mastering Stable Art: Unveiling Key Factors Influencing Physical Stability of Amorphous Solid Dispersions
Meet the Crystal Pharmatech formulation team next week at CPHI
Crystal Pharmatech and the Future of Pharma at AAPS PharmSci 360
Crystal Formulation Services' GMP Manufacturing Facility Successfully Passes the Remote Audit by US Client, Marking a Key Milestone for Its International Expansion
ASD Column | How to Select Polymers in Hot-melt Extrusion Process?
Crystal Pharmatech Raring to Go to ChemOutsourcing 2022
ASD Column | Understanding the ASD Preparation Methods and Selecting the Optimal Method for Solution
Crystal Bio Welcomes Dr. Shiaw-Lin (Billy) Wu as Co-Founder and Chief Scientific Officer
CPHI North america - Meet Us at Booth #530
Polymorphs, Solvatomorphs and Hydrate of Dabrafenib
Crystal Bio Appoints Dr. Ye Gu as Co-founder, CTO, and Head of USA BD
Shining Glory: Unveiling the "True Eye" behind the Veil of Drug Crystal Forms
Crystal Pharmatech's CDMO Business Unit - Crystal Formulations Services Successfully Passed EU QP Audit
Applications of Dynamic Moisture Adsorption in Crystal Research
Meet Crystal Pharmatech at AAPS National Biotechnology Conference
Application of Granularity Analysis in Crystal Typing Research
Assessment of CQA in mRNA-LNP Modality
DCAT Week 2025
A Brief Introduction to Amorphous Solid Dispersion Technology
ADME Simulations: Insights into Bioavailability and Pharmacokinetics
Understand ASD Manufacturing Strategies, Choose the Optimal One
Parameter Sensitivity with GastroPlus
Review of Polymorph Patent Application of 30 Small Molecule New Drugs Approved by the FDA in 2023
Unveil Key Factors Influencing the Physical Stability of Amorphous Solid Dispersions
Characterization and Evaluation of Amorphous Solid Dispersion (ASD) - Part 1
Optimizing Polymer Selection for Amorphous Solid Dispersion in Hot Melt Extrusion Processes
Analytical Chemistry
Pre-formulation Studies
Formulation Development
Clinical and Commercial Manufacturing
Solid Form Screening
Solid Form Developability Evaluation
Absolute Structure Determination
Crystallization Process Development
The Purpose Behind Molecules to Medicine
Repurposing Dexmedetomidine into an Oral Sleep-Enhancing Medication
The Role of Collaboration in Optimizing the Development of HIF Inhibitors for the Treatment of Advan
Mol2Med™ Integrated Services
AAPS 2024 PHarmSCi 360
Concerned about mRNA -LNP Integrity during International Shipping?
Improving the Manufacture of mRNA Biologics
Home
Formulation Development
Solid Form Screening and Selection
Our Company
Talent Recruitment
Case Study 1: Indinavir - Early Salt Form Change
The Tiny-TIM System
Technical Articles
Solid Form Research
Engineering Cocrystal Solubility and Streamlining Cocrystal Early Development
The Use of Amorphous Solid Dispersions to Enhance Dissolution, and Oral Bioavailability of Poorly Water-Soluble Pharmaceutical C
Biologics CMC Analytical Services
High-Resolution Mass Spectrometry
Crystal Pharmatech Formulation Forum
News & Events
Optimizing Polymer Selection for Amorphous Solid Dispersion in Hot Melt Extrusion Processes
Unlocking the Power of AI in Pharmaceutical Development
Formulation & Delivery US 2024
Concerned about mRNA -LNP Integrity during International Shipping?
Analytical Techniques to Assess the mRNA 5' Cap
Small Molecule
Solid-State Characterization/FAST
Conventional Oral Solid Dosage Forms
Our History
News
Our Business
Case Study 2: DPC 961 – Form Change On A Fast Track Compound
Detecting and Avoiding Disappearing Polymorph Cases by Crystal Structure Prediction
Presentations
Preclinical and Tox Formulation Development
Synthonic Engineering: Tools for the Rational Design of High Quality Pharmaceuticals
Polymorphism of Drugs - Can We Exploit Physical Form in the Development of Low Solubility Molecules?
Bioanalysis and Biomarker Services
2023-Mol2Med™ First-Time-Right Approach Webinar Series
Date:
2:00-3:00 pm EDT, Wednesday,
Watch on-demand
Developability Assessment
Oral Solid Dosage Forms
Development and Production Application Cases of Amorphous Solid Dispersion Formulations (II) - Spray Drying
CATUG and Crystal Bio Establish Strategic Partnership, Launching “CATUG-Crystal” Joint Lab Dedicated to Advanced Nucleic Acid Analytical Services
Characterization and Evaluation of Amorphous Solid Dispersion - Part 2
ADME Simulations: Insights into Bioavailability and Pharmacokinetics
Utilizing Compaction Simulation for Advancing Oral Dosage Formulation Design
Critical Quality Attribute (CQA) in Antibody Drug Conjugate (ADC) Modality
The 16th Drug Discovery Strategic Summit (DDSS) - San Francisco
Bioanalytical and Biomarker Services
Single Crystal Growth & Structure Determination
Bioavailability Enhancement for Insoluble Compounds & PROTAC & Oral Peptides
Our People
Events
Case Study 3: Atorvastatin - Crystalline Form Change In Late Development
Selecting the Right API Form and Formulation
Instrumentation for Electron Diffraction, Applications, and Case Studies
Case Studies
Effective Development of API Crystallization Processes During Drug Development
Efficient Preclinical Formulation Development for Poorly Soluble Compounds
pKa/LogP/LogD Measurements
Date:
2:00-3:00 pm EDT, Wednesday,
Watch on-demand
Amorphous Solid Dispersion (Spray Drying & Hot-melt Extrusion)
Dr. LianFeng Huang Joins Crystal Pharmatech as Chief Scientist
Characterization and Evaluation of Amorphous Solid Dispersion (ASD) - Part 1
Characterization and Evaluation of Amorphous Solid Dispersion-Part 2
Parameter Sensitivity with GastroPlus
Critical Quality Attribute D0 Impact in ADC Modality
SAPA Annual Conference (Gold Corporate Sponsorship)
Crystal Bio Solutions
Bio Analytics
API Form and Solid-State Research
Crystallization Development
Mini-tablet
Knowledge Hub
Molecules-to-Medicine: Accelerating Drug Development through Collaboration
PBPK in Preclinical/FIH Scenarios
Whitepaper
Case Study 4: Gatifloxacin - Crystalline Form Changes With A Licensed Compound
Amorphous Solid Dispersions
Using Thermodynamic Phase Maps in API Crystallization Process Design
Pre-clinical Formulation Strategies Sponsored by Crystal Pharmatech
Date:
2:00-3:00 pm EDT, Wednesday,
Whatch on-demand
Stability and Solubility Studies
Comprehensive Physicochemical Property Evaluation
Pediatric Formulation (Mini-tablet)
Crystal Formulation Services successfully passed the dual certification of GMP and GDP conducted by SGS
Development and Production Application Cases of Amorphous Solid Dispersion Formulations (I) - Hot Melt Extrusion
Unveil Key Factors Influencing the Physical Stability of Amorphous Solid Dispersions
Assessment of CQA in mRNA-LNP Modality
Overcoming Bioavailability Barrier to Deliver Protein Degraders
14th American Drug Delivery and Formulation Summit (Exhibit)
Developability Assessment, Pre-formulation Study for IND Enabling
Product Quality Analysis
Additional Capabilities
Chiral Separation
Technology
Our Partner
Advanced Characterization: Tools for Accelerating Molecules to Medicine
Tools for Accessing New Solid Forms
Case Study 5: Lifecycle Management - Olanzapine - Crystalline Change From Free Acid to Salt
Enabling Poorly Soluble Weak Bases for Improved Bioavailability: Why a Salt May Not be the Best Choice
Integrated Phase and Formulation Selection to Support GLP Toxicology and First in Human Studies Sponsored by Crystal Pharmatech
In-Silico PBPK Modeling and Simulation
Industry Shift: FDA Goes Vegan?
Date:
2:00-3:00 pm EDT, Wednesday,
Watch on-demand
Crystallization Development Services
Excipient Selection and Compatibility Studies
Analytical Chemistry
ASD Series
Unlock Solubility Enhancement Methods for Poorly Soluble Oral Drugs
Development and Production Application Cases of Amorphous Solid Dispersion Formulations (II) - Spray Drying
Overcoming Poor Solubility and Dissolution of Insoluble Molecules
Patent Analysis of Resmetirom
Sterility Assays in Drug/Device Manufacturing
2024 CASSS - Mass Spec Symposium
Flow Cytometry
About Us
Pre-formulation Studies
Formulations for PK/Efficacy/Tox Studies
Crystallization and Spray Drying Process Development, Scale-Up, and Technology Transfer
Case Study 6: Oxybutynin- Crystalline Change From Salt to Free Base
Learn about Drug Eutectic Screening
Crystal Pharmatech's CDMO Business Unit - Crystal Formulation Services Received China Drug Product Manufacturing License, Achieving the Important Milestone in Formulation Capability
Development and Production Application Cases of Amorphous Solid Dispersion Formulations (I) - Hot Melt Extrusion
Review of Polymorph Patent Application of 30 Small Molecule New Drugs Approved by the FDA in 2023
Biologics
ChemOutsourcing 2024
Crystal Bio Webinar
ELISpot Assays
Solid-State NMR Analysis
Resources
Avoiding Drug Failures: Right First Time; Fast First Time
Exploring the Pharmaceutical Solid State by Molecular Simulation
Crystallization Process Method
SMART Development of Pre-clinical Candidates
Crystal Pharmatech Recognized as "Best Partner" by Allorion Therapeutics for Excellent Services
Formulation and Analytical Development
Animal Dosing Vehicle Selection
Detecting Low-Level Crystallinity in ASD-like Samples Using ssNMR Techniques
Understand ASD Manufacturing Strategies, Choose the Optimal One
Immuno-Oncology Summit 2024 - Meet Crystal Bio at Booth 15
Molecular Biology
Clinical and Commercial Manufacturing
Amorphous Solid Dispersions
Careers
Tools and Strategies for De-risking Rapid Drug Substance and Drug Product Development
API Crystallization
Crystal Pharmatech Returned to AAPS 2022 PharmSci 360
Fun Sharing: The Secret Behind the Silky Smoothness of Chocolate (Part 2)
GMP Manufacturing
A Brief Introdction to Amorphous Solid Dispersion Technology
Amorphous Solid Dispersions: Two Heads Are Better Than One
FIH-PMF-FMF Manufacturing
The Bioprocessing Summit 2024 - Meet Crystal Bio at Booth T13
Contact Us
Crystal Pharmatech and Particle Sciences Form a US-China Pharmaceutical CRO Partnership
Advancements in Analytical Tools for API and DP Characterization
Co-crystals
Fun Sharing: The Secret behind the Silky Smooth Enjoyment of Chocolate (Part 3)
Unlock Solubility Enhancement Methods for Poorly Soluble Oral Drugs
Meet Crystal Pharmatech at 2024 Controlled & Modified Drug Release Summit
Assessment of Powder Segregation in Direct Compression (DC) Blends: Developing Predictive and PAT Tools
Search Result
Webinar Series
Crystal Pharmatech Raises $10 Million to Accelerate Growth
Solid Forms: The Good; The Bad; The Ugly
Impact of Solid-state in Early Development
Fun Sharing: The Secret Behind the Silkiness of Chocolate (Part 1)
Join Crystal Pharmatech for the Sino-American Pharmaceutical Professionals Association (SAPA) NE 26th Annual Conference
Formulation Design and Development of Fixed Dose Combination Solid Oral Dosage Forms
Sitemap
Crystal Formulation Services, Formulation Tailor-made for Your Molecules
Utility of Single Crystal in Form and Formulation Selection
Optimal Preclinical Formulation Development
Crystal Pharmatech will be in San Diego from June 3-6 at BIO International Convention
Drug Delivery and Patient Centric Approaches to Drug Development
404
Candoo Enables the Successful Development of a BCS 4 Combo Drug Product
Introduction to MicroED Technology and Solutions
Salts
Fun Sharing:The Story Between Ice Crystals and Frozen Foods (Part 3)
Meet Crystal Pharmatech at Chinese Antibody Society 2024 Annual Conference
Privacy Policy
International Company Crystal Pharmatech Finds CCIT An Optimal Spot for First US Location
Formulation Implications
Pharmaceutical Solid-state Forms
Meet Crystal Pharmatech at 15th Drug Discovery Strategic Summit (DDSS)
Submission Successful!
Crystal Pharmatech Triples Headquarters in Biobay, China, with More Floors and Labs
Fun Sharing: The Relationship Between Ice Crystals and Frozen Foods (Part 1)
Clinical Supply
Meet Crystal Pharmatech at Sorption Symposium North America 2024
Taggg
Xceleron and Crystal Pharmatech Announce Partnership to Improve Early Clinical Development Utilizing Absolute Bioavailability Trials and Solid-State Solutions
CPHI North America - Meet Crystal Pharmatech at Booth 1441
Search Result Service
Crystal Pharmatech Introduces Customized Service Packages for Customers Seeking Materials Science Approaches in Drug Discovery and Development
Fun Sharing: The Story of Ice Crystals and Frozen Foods (Part 2)
Meet Crystal Pharmatech at MIDD+ Boston 2024
Search Result Others
Crystal Pharmatech Expands Leadership Team
Case Study on Development and Production Applications of Amorphous Solid Dispersions - Hot Melt Extrusion
Formulation Development: Fastest-to-FIH Without Sacrificing Quality
Crystal Formulation Services(CFS)Opens New Formulation Development Center and Analytical R&D Lab in Suzhou, China
event page
Development and Production Application Case Study of Amorphous Solid Dispersions: Spray Drying
DCAT WEEK: CMC Discussions
Amorphous Solid Dispersion Technology and the Service Advantages of Crystal Pharmaceutical
AAPS PharmSci360 - Meet Us at Booth # 2106
Candoo's Formulation Technology Platform Featured in the Drug Development & Delivery Journal
ASD Column | Mastering Stable Art: Unveiling Key Factors Influencing Physical Stability of Amorphous Solid Dispersions
Meet the Crystal Pharmatech formulation team next week at CPHI
Crystal Pharmatech and the Future of Pharma at AAPS PharmSci 360
Crystal Formulation Services' GMP Manufacturing Facility Successfully Passes the Remote Audit by US Client, Marking a Key Milestone for Its International Expansion
ASD Column | How to Select Polymers in Hot-melt Extrusion Process?
Crystal Pharmatech Raring to Go to ChemOutsourcing 2022
ASD Column | Understanding the ASD Preparation Methods and Selecting the Optimal Method for Solution
Crystal Bio Welcomes Dr. Shiaw-Lin (Billy) Wu as Co-Founder and Chief Scientific Officer
CPHI North america - Meet Us at Booth #530
Polymorphs, Solvatomorphs and Hydrate of Dabrafenib
Crystal Bio Appoints Dr. Ye Gu as Co-founder, CTO, and Head of USA BD
Shining Glory: Unveiling the "True Eye" behind the Veil of Drug Crystal Forms
Crystal Pharmatech's CDMO Business Unit - Crystal Formulations Services Successfully Passed EU QP Audit
Applications of Dynamic Moisture Adsorption in Crystal Research
Meet Crystal Pharmatech at AAPS National Biotechnology Conference
Application of Granularity Analysis in Crystal Typing Research
Assessment of CQA in mRNA-LNP Modality
DCAT Week 2025
A Brief Introduction to Amorphous Solid Dispersion Technology
ADME Simulations: Insights into Bioavailability and Pharmacokinetics
Understand ASD Manufacturing Strategies, Choose the Optimal One
Parameter Sensitivity with GastroPlus
Review of Polymorph Patent Application of 30 Small Molecule New Drugs Approved by the FDA in 2023
Unveil Key Factors Influencing the Physical Stability of Amorphous Solid Dispersions
Characterization and Evaluation of Amorphous Solid Dispersion (ASD) - Part 1
Optimizing Polymer Selection for Amorphous Solid Dispersion in Hot Melt Extrusion Processes
Quick Links
About Us
Events
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
bd_global@crystalpharmatech.com
+1-609-604-8303
+1-609-604-8303
Your browser does not support VBScript!